Video

What the re:Vive 2.0 platform may mean for the future of vision diagnostics

Author(s):

Sheryl Stevenson

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director.

Related Videos
Image credit: ©Ophthalmology Times
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company
January 19th 2025

InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Ashvattha Therapeutics secures $50M in financing to advance clinical trials
January 15th 2025

Ashvattha Therapeutics secures $50M in financing to advance clinical trials

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery
January 14th 2025

Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery

4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME
January 13th 2025

4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME

© 2025 MJH Life Sciences

All rights reserved.